Citadel Advisors
ORIC icon

Citadel Advisors’s Oric Pharmaceuticals ORIC Stock Holding History

Citadel Advisors’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$28.1M Buy
2,595,299
+172,558
+7% +$1.56M ﹤0.01% 2177
2026
Q1 		$30.7M Sell
2,422,741
-11,969
-0.5% -$136K 0.01% 1843
2025
Q4 		$19.9M Buy
2,434,710
+1,236,706
+103% +$14.2M ﹤0.01% 2349
2025
Q3 		$14.4M Sell
1,198,004
-204,764
-15% -$2.15M ﹤0.01% 2748
2025
Q2 		$14.2M Buy
1,402,768
+890,879
+174% +$5.98M ﹤0.01% 2581
2025
Q1 		$2.86M Buy
511,889
+475,463
+1,305% +$4.16M ﹤0.01% 4855
2024
Q4 		$294K Buy
36,426
+30,659
+532% +$281K ﹤0.01% 9697
2024
Q3 		$59.1K Buy
+5,767
New +$57K ﹤0.01% 11727
2023
Q4 		– Sell
-145,007
Closed -$877K – 14958
2023
Q3 		$877K Buy
145,007
+66,732
+85% +$547K ﹤0.01% 6852
2023
Q2 		$607K Sell
78,275
-41,328
-35% -$235K ﹤0.01% 7508
2023
Q1 		$682K Buy
119,603
+40,970
+52% +$214K ﹤0.01% 7637
2022
Q4 		$463K Buy
78,633
+66,196
+532% +$223K ﹤0.01% 8401
2022
Q3 		$40K Sell
12,437
-187,950
-94% -$752K ﹤0.01% 11760
2022
Q2 		$898K Sell
200,387
-30,300
-13% -$121K ﹤0.01% 7266
2022
Q1 		$1.23M Buy
+230,687
New +$2.08M ﹤0.01% 7226
2021
Q4 		– Sell
-15,377
Closed -$322K – 14469
2021
Q3 		$322K Sell
15,377
-3,938
-20% -$79.8K ﹤0.01% 10903
2021
Q2 		$342K Buy
+19,315
New +$423K ﹤0.01% 10951
2021
Q1 		– Sell
-40,435
Closed -$1.37M – 13563
2020
Q4 		$1.37M Sell
40,435
-26,772
-40% -$768K ﹤0.01% 6126
2020
Q3 		$1.68M Buy
67,207
+60,376
+884% +$1.44M ﹤0.01% 5053
2020
Q2 		$230K Buy
+6,831
New +$218K ﹤0.01% 8329

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Citadel Advisors's ORIC Position: Q2 2026 in Review

Citadel Advisors increased its Oric Pharmaceuticals (ORIC) stake by 7.1% in Q2 2026, buying an estimated $1.56M and bringing the position to 2,595,299 shares worth $28.1M. The position accounts for ﹤0.01% of the portfolio, ranked #2177.

Citadel Advisors first reported a position in ORIC in Q2 2020 and has held it in 20 quarters since. The position peaked at $30.7M in Q1 2026. 181 funds tracked by Wall St. Rank hold ORIC as of Q2 2026.

  • Citadel Advisors held 2,595,299 shares of Oric Pharmaceuticals worth $28.1M as of Q2 2026.
  • Citadel Advisors bought 172,558 Oric Pharmaceuticals shares in Q2 2026, an estimated $1.56M.
  • Oric Pharmaceuticals made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #2177 holding.
  • Citadel Advisors first reported a position in Oric Pharmaceuticals in Q2 2020 and has held it in 20 quarters since.
  • Citadel Advisors's Oric Pharmaceuticals position peaked at $30.7M in Q1 2026.
  • 181 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.